Holder Sio Capital Management LLC Has Boosted Sage Therapeutics INC (Put) (SAGE) Stake

March 14, 2018 - By Nellie Frank

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.23, from 0.98 in 2017Q2. It is positive, as 33 investors sold SAGE shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported. State Board Of Administration Of Florida Retirement System invested in 0% or 16,852 shares. Loring Wolcott And Coolidge Fiduciary Advsr Ltd Liability Partnership Ma accumulated 50 shares or 0% of the stock. 77 are owned by Reilly Finance Advsr Lc. Franklin Resources has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Prudential has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Keybank Natl Association Oh has 3,244 shares for 0% of their portfolio. Legal General Group Public Ltd Com holds 14,820 shares. Rhenman & Prtn Asset Mngmt stated it has 0.4% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Citigroup reported 0% stake. Goldman Sachs Grp has 338,078 shares for 0.01% of their portfolio. Guggenheim Cap Lc holds 84,088 shares. Swiss National Bank & Trust invested in 53,300 shares or 0% of the stock. Tudor Inv Corp Et Al has 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 4,815 shares. Moreover, Jabre Prtnrs has 0.07% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 6,000 shares. Citadel Advisors Ltd Llc invested in 108,200 shares or 0.01% of the stock.

Since December 14, 2017, it had 0 insider purchases, and 3 sales for $27.36 million activity. The insider PAUL STEVEN M sold $10.00M. 60,000 shares were sold by Robichaud Albert, worth $9.57M on Thursday, December 14.

Sio Capital Management Llc increased its stake in Sage Therapeutics Inc (Put) (SAGE) by 217.33% based on its latest 2017Q3 regulatory filing with the SEC. Sio Capital Management Llc bought 130,400 shares as the company’s stock rose 0.86% with the market. The institutional investor held 190,400 shares of the health care company at the end of 2017Q3, valued at $11.86M, up from 60,000 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Sage Therapeutics Inc (Put) for a number of months, seems to be bullish on the $7.96 billion market cap company. The stock decreased 0.05% or $0.08 during the last trading session, reaching $173.83. About 194,088 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since March 14, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Sio Capital Management Llc, which manages about $116.75M and $192.73M US Long portfolio, decreased its stake in Advanced Accelerator Applications Sa by 55,941 shares to 52,582 shares, valued at $3.56M in 2017Q3, according to the filing.

More news for Sage Therapeutics, Inc. (NASDAQ:SAGE) were recently published by: Benzinga.com, which released: “Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy” on February 26, 2018. Businesswire.com‘s article titled: “Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial …” and published on February 22, 2018 is yet another important article.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 55 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, October 26. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, December 7 report. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by BMO Capital Markets on Thursday, August 3. RBC Capital Markets maintained the shares of SAGE in report on Thursday, February 22 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Thursday, June 23. The firm has “Buy” rating by Bank of America given on Thursday, November 16. The rating was upgraded by Chardan Capital Markets on Friday, November 10 to “Buy”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, November 9 by BMO Capital Markets. Cowen & Co maintained it with “Buy” rating and $10000 target in Thursday, August 3 report. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Outperform” rating by BMO Capital Markets on Wednesday, June 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.